Urinary Tract Infection News and Research

RSS

Urinary tract infections are a serious health problem affecting millions of people each year. Infections of the urinary tract are the second most common type of infection in the body. Urinary tract infections (UTIs) account for about 8.3 million doctor visits each year.* Women are especially prone to UTIs for reasons that are not yet well understood. One woman in five develops a UTI during her lifetime. UTIs in men are not as common as in women but can be very serious when they do occur.

International research sheds light on Escherichia coli

An unprecedented picture of how bacteria latch on to human cells has been published by UK, French and US scientists. They have produced a finely detailed model of one of the tools used by some of the nastiest varieties of the stomach bug, Escherichia coli, to stick to and gain entry to host cells.

1 Sep 2004

Study to compare prostate surgery and drugs

The Minimally Invasive Surgical Therapies (MIST) Consortium for Benign Prostatic Hyperplasia (BPH) has launched a new study to compare long-term benefits and risks of transurethral needle ablation (TUNA) and transurethral microwave thermotherapy (TUMT) to a regimen of the alpha-1 inhibitor alfuzosin and the 5-alpha reductase inhibitor finasteride.

20 Aug 2004

Increase in the number of urinary tract infections and cases of blood poisoning caused by strains of E. coli

The Health Protection Agency has detected an increase in the number of urinary tract infections (UTIs) and cases of blood poisoning caused by strains of E. coli that are resistant to most antibiotics.

17 Jul 2004

TUNA therapy results in significantly reduced erectile dysfunction

Comparing five-year results of Medtronic TUNA® Therapy (transurethral needle ablation) to surgery for 121 men in their mid-60s with lower urinary tract symptoms caused by an enlarged prostate, a team of urologists found that “for appropriately selected patients with bothersome voiding symptoms, TUNA is an attractive treatment option.”

1 Jul 2004

Study shows herpes is common in suburban populations, with Denver up to 20 percent

According to a recent study of 36 primary care physician (PCP) offices in relatively affluent suburban areas of six U.S. cities, one in four people (25.5 percent) tested positive for the virus that causes genital herpes, despite the fact that only four percent of all those tested reported a history of the condition.

24 May 2004

Botox shows promise as an alternative treatment for benign prostatic hyperplasia

Injections of botulinum toxin A (botox) into the prostate are a promising alternative treatment for the millions of men who have benign prostatic hyperplasia (BPH), a condition commonly referred to as enlarged prostate, according to a study conducted by the University of Pittsburgh School of Medicine and Chang Gung Memorial Hospital in Taiwan.

11 May 2004

Sexual Dysfunction in benign prostatic hyperplasia (BPH) twice as high as physicians estimate

The incidence of sexual dysfunction in patients suffering from Benign Prostatic Hyperplasia (BPH) -- or enlarged prostate -- is nearly twice as high as treating physicians believe shows a new survey from the American Foundation for Urologic Diseases (AFUD) presented today at the American Urological Association annual meeting.

11 May 2004

Study shows those with weak immune systems should avoid the shower

A study out of the San Diego State University Center for Microbial Sciences reveals that hundreds of millions of colorful bacteria thrive on shower curtains, waiting to attack those who think they are getting clean.

3 May 2004

New Australian report outlines the health benefits of breastfeeding

A new report released by the NSW Centre for Public Health Nutrition, Australia outlines the health benefits of breastfeeding, which is the foundation for a lifetime of good health.

25 Apr 2004

New drug to treat urinary tract infections, a step closer

Depomed, Inc. today announced top line results from the Phase III clinical trial of its Ciprofloxacin GR, an extended release formulation of ciprofloxacin HCl, which is used to treat urinary tract infections. The data confirmed Phase II results, demonstrating that Depomed's once-daily Ciprofloxacin GR eliminated the organisms responsible for urinary tract infections as effectively as twice-daily CIPRO(R), but with fewer gastrointestinal side effects, specifically fewer incidences of nausea and diarrhea.

22 Mar 2004